Amgen's bone drug Xgeva gains initial support from U.K. agency

04/3/2012 | PMLive.com (U.K.)

The U.K. National Institute for Health and Clinical Excellence gave preliminary recommendation on Amgen's Xgeva, or denosumab, for treating bone metastasis in some cancer patients. Xgeva should be offered to the National Health Service at a discount, NICE said.

View Full Article in:

PMLive.com (U.K.)

Published in Brief: